Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

M, Klinger; C, Brandl; G, Zugmaier; Y, Hijazi; RC, Bargou; MS, Topp; N, Gökbuget; S, Neumann; M, Goebeler; A, Viardot; M, Stelljes; M, Brüggemann; D, Hoelzer; E, Degenhard; D, Nagorsen; PA, Baeuerle; A, Wolf; P, Kufer

doi:10.1182/blood-2012-01-400515

Public

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Published in Blood • May 16, 2012

Authors:

Klinger M

Brandl C

Zugmaier G

Abstract

T cell-engaging CD19/CD3-bispecific BiTE Ab blinatumomab has shown an 80% complete molecular response rate and prolonged leukemia-free survival in patients with minimal residual B-lineage acute lymphoblastic leukemia (MRD(+) B-ALL). Here, we report that lymphocytes in all patients of a phase 2 study...

View

Paywalled

View Full Text

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Generate AI Take for this paper

Discussions